Schor Chen 4
4 · Adicet Bio, Inc. · Filed Aug 16, 2023
Insider Transaction Report
Form 4
Adicet Bio, Inc.ACET
Schor Chen
DirectorPresident & CEO
Transactions
- Award
Stock Option (Right to Buy)
2023-08-14+421,600→ 421,600 totalExercise: $2.14Exp: 2031-02-11→ Common Stock (421,600 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+36,857→ 36,857 totalExercise: $2.14Exp: 2029-12-05→ Common Stock (36,857 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−384,900→ 0 totalExercise: $9.05Exp: 2033-01-23→ Common Stock (384,900 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−36,857→ 0 totalExercise: $8.89Exp: 2029-12-05→ Common Stock (36,857 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+872,111→ 872,111 totalExercise: $2.14Exp: 2030-09-16→ Common Stock (872,111 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−421,600→ 0 totalExercise: $16.82Exp: 2031-02-11→ Common Stock (421,600 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+295,000→ 295,000 totalExercise: $2.14Exp: 2032-01-06→ Common Stock (295,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−872,111→ 0 totalExercise: $16.11Exp: 2030-09-16→ Common Stock (872,111 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−240,000→ 0 totalExercise: $13.27Exp: 2031-01-12→ Common Stock (240,000 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+240,000→ 240,000 totalExercise: $2.14Exp: 2031-01-12→ Common Stock (240,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−295,000→ 0 totalExercise: $15.52Exp: 2032-01-06→ Common Stock (295,000 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+384,900→ 384,900 totalExercise: $2.14Exp: 2033-01-23→ Common Stock (384,900 underlying)
Footnotes (9)
- [F1]Reflects 1-for-7 reverse stock split effected by the Issuer on September 15, 2020.
- [F2]On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F3]The shares subject to this option are fully vested and exercisable as of the date hereof.
- [F4]The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
- [F5]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F6]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F7]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F8]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F9]The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.